Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
Long-term clinical outcome of titanium-nitride-oxide-coated stents versus everolimus-eluting stents in acute coronary syndrome: Final report of the BASE ACS trial
International Journal of Cardiology, Volume 222, Year 2016
Notification
URL copied to clipboard!
Description
Background The BASE ACS randomized trial demonstrated non-inferiority of titanium-nitride-oxide-coated bioactive stents (BAS), compared with everolimus-eluting stents (EES), for the primary endpoint of major adverse cardiac events (MACE) in patients presenting with acute coronary syndrome (ACS) at 12-month follow-up. We report the final long-term clinical outcome of the trial. Methods We randomly assigned 827 patients with ACS to receive either BAS (417) or EES (410). The primary endpoint was MACE: a composite of cardiac death, non-fatal myocardial infarction (MI) or ischemia-driven target lesion revascularization (TLR) at 12-month follow-up. Analysis was performed by intention to treat. Follow-up was planned at 12 months, and yearly thereafter through 7 years. Results Mean follow-up duration was 4.2 ± 1.9 years (median 5.0 years). At 5-year follow-up, BAS was non-inferior to EES for the primary endpoint of MACE (14.4% versus 17.8%, respectively; hazard ratio for BAS versus EES, 0.82; 95% confidence interval, 0.58–1.16; p = 0.26 for superiority; p < 0.001 for non-inferiority). The rate of non-fatal MI was lower in the BAS group (5.9% versus 9.7%, respectively, p = 0.028). The rates of cardiac death and ischemia-driven TLR were comparable (2.8% versus 3.8%, and 8.3% versus 9.9%; p = 0.76 and p = 0.58, respectively). Conclusions In the current final report of the randomized BASE ACS trial in patients with ACS, BAS implantation was associated with a rate of cumulative MACE at long-term follow-up that was statistically non-inferior to EES. © 2016 Elsevier Ireland Ltd
Authors & Co-Authors
Karjalainen, Pasi Paavo
Finland, Pori
Satakunta Central Hospital
Nammas, Wail M.
Finland, Pori
Satakunta Central Hospital
Ylitalo, Antti S.
Finland, Pori
Satakunta Central Hospital
de Belder, Adam J.
United Kingdom, Worthing
University Hospitals Sussex Nhs Foundation Trust
Airaksinen, Juhani K.E.
Finland, Turku
Turun Yliopistollinen Keskussairaala
Statistics
Citations: 20
Authors: 5
Affiliations: 7
Identifiers
Doi:
10.1016/j.ijcard.2016.07.267
ISSN:
01675273
Research Areas
Environmental
Noncommunicable Diseases
Study Design
Cohort Study